Literature DB >> 25048618

Posttranscriptional changes of serum albumin: clinical and prognostic significance in hospitalized patients with cirrhosis.

Marco Domenicali1, Maurizio Baldassarre, Ferdinando A Giannone, Marina Naldi, Marianna Mastroroberto, Maurizio Biselli, Maristella Laggetta, Daniela Patrono, Carlo Bertucci, Mauro Bernardi, Paolo Caraceni.   

Abstract

UNLABELLED: Beside the regulation of fluid distribution, human serum albumin (HSA) carries other activities, such as binding, transport, and detoxification of many molecules. In patients with cirrhosis, HSA exhibits posttranscriptional alterations that likely affect its functions. This study aimed at identifying the structural HSA alterations occurring in cirrhosis and determining their relationship with specific clinical complications and patient survival. One hundred sixty-eight patients with cirrhosis, 35 with stable conditions and 133 hospitalized for acute clinical complications, and 94 healthy controls were enrolled. Posttranscriptional HSA molecular changes were identified and quantified by using a high-performance liquid chromatography/electrospray ionization mass spectrometry technique. Clinical and biochemical parameters were also recorded and hospitalized patients were followed for up to 1 year. Seven HSA isoforms carrying one or more posttranscriptional changes were identified. Altered HSA isoforms were significantly more represented in patients than in healthy controls. Conversely, the native, unchanged HSA isoform was significantly reduced in cirrhosis. Native HSA and most altered isoforms correlated with both Child-Pugh and Model for End-Stage Liver Disease scores. In hospitalized patients, oxidized and N-terminal truncated isoforms were independently associated with ascites, renal impairment, and bacterial infection. Finally, the native HSA and cysteinylated/N-terminal truncated isoforms were predictors of 1-year survival, with greater prognostic accuracy than total serum albumin concentration.
CONCLUSIONS: Extensive posttranscriptional changes of HSA, involving several molecular sites and increasing in parallel with disease severity, occur in patients with cirrhosis. Altered isoforms are independently associated with specific clinical complications, whereas the residual, native HSA isoform independently predicts patient survival. These findings support the concept of the "effective albumin concentration," which implies that the global HSA function is related not only to its serum concentration, but also to the preservation of its structural integrity.
© 2014 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25048618     DOI: 10.1002/hep.27322

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  41 in total

1.  Controlling Nutritional Status (CONUT) score is a prognostic marker for gastric cancer patients after curative resection.

Authors:  Daisuke Kuroda; Hiroshi Sawayama; Junji Kurashige; Masaaki Iwatsuki; Tsugio Eto; Ryuma Tokunaga; Yuki Kitano; Kensuke Yamamura; Mayuko Ouchi; Kenichi Nakamura; Yoshifumi Baba; Yasuo Sakamoto; Yoichi Yamashita; Naoya Yoshida; Akira Chikamoto; Hideo Baba
Journal:  Gastric Cancer       Date:  2017-06-27       Impact factor: 7.370

Review 2.  Human albumin solution for patients with cirrhosis and acute on chronic liver failure: Beyond simple volume expansion.

Authors:  Christopher Valerio; Eleni Theocharidou; Andrew Davenport; Banwari Agarwal
Journal:  World J Hepatol       Date:  2016-03-08

Review 3.  Albumin in chronic liver disease: structure, functions and therapeutic implications.

Authors:  Rosaria Spinella; Rohit Sawhney; Rajiv Jalan
Journal:  Hepatol Int       Date:  2015-09-29       Impact factor: 6.047

4.  Medicine use and medicine-related problems in patients with liver cirrhosis: a systematic review of quantitative and qualitative studies.

Authors:  Ejaz Cheema; Aliaa Al-Aryan; Abdullah Al-Hamid
Journal:  Eur J Clin Pharmacol       Date:  2019-05-11       Impact factor: 2.953

Review 5.  Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure.

Authors:  Jonel Trebicka; Peer Bork; Aleksander Krag; Manimozhiyan Arumugam
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-11-30       Impact factor: 46.802

Review 6.  Role of human albumin in the management of complications of liver cirrhosis.

Authors:  Mauro Bernardi; Carmen S Ricci; Giacomo Zaccherini
Journal:  J Clin Exp Hepatol       Date:  2014-09-19

7.  Albumin binding function is a novel biomarker for early liver damage and disease progression in non-alcoholic fatty liver disease.

Authors:  Lejia Sun; Qing Wang; Meixi Liu; Gang Xu; Huanhuan Yin; Dongyue Wang; Feihu Xie; Bao Jin; Yukai Jin; Huayu Yang; Junying Zhou; Yilei Mao
Journal:  Endocrine       Date:  2020-05-12       Impact factor: 3.633

8.  Human serum albumin presents isoform variants with altered neonatal Fc receptor interactions.

Authors:  Yann Leblanc; Marie Berger; Alexander Seifert; Nicolas Bihoreau; Guillaume Chevreux
Journal:  Protein Sci       Date:  2019-11       Impact factor: 6.725

Review 9.  Impaired albumin function: a novel potential indicator for liver function damage?

Authors:  Lejia Sun; Huanhuan Yin; Meixi Liu; Gang Xu; Xiaoxiang Zhou; Penglei Ge; Huayu Yang; Yilei Mao
Journal:  Ann Med       Date:  2019-11-21       Impact factor: 4.709

Review 10.  Albumin: Indications in chronic liver disease.

Authors:  Manuel Tufoni; Giacomo Zaccherini; Paolo Caraceni; Mauro Bernardi
Journal:  United European Gastroenterol J       Date:  2020-02-26       Impact factor: 4.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.